Skip to main content
. Author manuscript; available in PMC: 2010 Jun 1.
Published in final edited form as: Cancer Lett. 2009 Aug 15;289(1):32–39. doi: 10.1016/j.canlet.2009.07.016

Table 2.

Frequencies of antibodies to 10 TAAs.

Type of serum No. sera No. and percentage of autoantibodies toa

Imp1 p62 Koc p53 CyclinB1 C-myc p16 survivin Any of 8 TAAs Sui1 RalA Any of 10 TAAs
HCCb 77 14c
(18.2)
13c
(16.9)
16c
(20.8)
14c
(18.2)
11c
(14.3)
9c
(11.7)
15c
(19.5)
9d
(11.7)
46c
(59.7)
9d
(11.7)
15c
(19.5)
51c
(66.2)
LC 30 0 (0) 1 (3.3) 4d (13.3) 2 (6.7) 0 (0) 1 (3.3) 4d (13.3) 0 (0) 9 (30) 1 (3.3) 1 (3.3) 10 (33.3)
CH 30 3 (10) 0 (0) 2 (6.7) 1 (3.3) 0 (0) 0 (0) 2 (6.7) 0 (0) 6 (20) 0 (0) 0 (0) 6 (20)
NHS 82 2 (2.4) 1 (1.2) 1 (1.2) 2 (2.4) 2 (2.4) 0 (0) 1 (1.2) 2 (2.4) 10 (12.2) 0 (0) 0 (0) 10 (12.2)
a

Cutoff value: mean + 3SD of NHS.

b

Abbreviations: HCC, hepatocellular carcinoma; LC, liver cirrhosis; CH, chronic hepatitis; NHS, normal human sera.

c

p values relative to NHS: p < 0.01.

d

p < 0.05.